Packaging And Labelling

news

interpack 2017, the Olympics of the global processing and packaging industry, is well under way in the beautiful city of Düsseldorf on the Rhine. Shanghai World of Packaging (swop), as a member of interpack alliance, used this great opportunity to present itself to more than 200,000 professionals and business men from all over the world.

news

Gerresheimer is showcasing its range of Duma Pocket containers at booth 4.2D02 at CPhI Worldwide in Frankfurt, Germany. The Duma Pocket containers are available in different sizes and colors and come with various closures. Gerresheimer is expanding its range of this tried-and-tested packaging with the addition of the 40-mL Duma CR box and the 100-mL Duma Pocket CR 100 for large filling volumes.

news

Gerresheimer, a manufacturer of primary packaging for the pharmaceutical industry, is presenting its new ready-to-fill vials (Gx RTF) at CPhI Worldwide 2017. Gerresheimer specializes in glass forming of vials from tubular glass and ready-to-fill processing of prefillable glass syringes. For the new Gx RTF vials, the company has combined its expertise with recognized Ompi EZ-Fill packaging technology.

news

West Pharmaceutical Services, a manufacturer of packaging components and delivery systems for the pharmaceutical industry, will present an educational seminar on the value of plastic caps for injectable drug vial closure at CPhI Worldwide 2017, taking place Oct. 24–26, 2017 in Frankfurt, Germany. West will also be showcasing its range of packaging components and drug delivery solutions, including NovaPure components, LyoSeal caps, and the SmartDose platform.

news

PCI Pharma Services (PCI), an outsourcing services provider, announced the acquisition of Millmount Healthcare, a pharmaceutical and healthcare contract packaging services provider. Millmount provides services in blister packaging, bottling, and tub filling, as well as in late-stage customization and cold chain packaging services. The acquisition supports PCI’s efforts to expand its clinical trial service offerings.

news

Romaco, supplier of processing and packaging equipment, will make its first joint appearance with packaging supplier Constantia Flexibles at CPhI Worldwide 2017. The two manufacturers have already been collaborating on research and development for many years.

news

Manufacturers introduce innovations in glass and plastic packaging for injectables. Glass has long served as the traditional primary package for parenteral products. Unfortunately, glass breaks relatively easily and has been known to cause particulate contamination, to delaminate, and to interact with the drug product.

news

The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.

news

Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute (NCI) study evaluating the safety and efficacy of a MAGE A3 T cell receptor (TCR) engineered T-cell therapy. The cancer testis antigen MAGE A3 is frequently found in many cancers including bladder, esophageal, cervical, head and neck, lung, and ovarian cancers, among others. The research, led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at NCI's Center for Cancer Research, was performed, in part, pursuant to a Cooperative Research and Development Agreement (CRADA) between NCI and Kite.

news

ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the completion of enrolment for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential genetically-targeted treatment for atrial fibrillation (AF). ARCA expects to report top-line Phase 2B data late in the first quarter of 2018.

news

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite.

news

Cancer Research UK and Newcastle University have extended their strategic drug discovery alliance with Astex Pharmaceuticals by three years to work on developing new cancer drugs and associated biomarkers.The alliance, formed five years ago, brings together researchers in structural and cellular biology

news

The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes

news

A new collaboration agreement between Cancer Research UK and Biotecnol will see an experimental immuno-oncology treatment move into early phase clinical trials for patients with advanced solid tumours, including lung cancers. lymphoblastic leukaemia (ALL).B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes

news

The government has privately raised objections to Chinese firm Shanghai FosunPharmaceutical Group's proposed $1.3-billion takeover of drug maker Gland Pharma, a source familiar with the matter said on Monday. The deal has won the approval of the Competition Commission of India (CCI), and the Foreign Investment Promotion Board (FIPB) in the last few months

news

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.Under the initiative, the MRC will fund up to five projects a year giving UK academic scientists access to UCB’s technologies in order to facilitate the potential discovery of new monoclonal antibodies, that can then be used to research the mechanisms of disease and identify novel therapeutic targets.

news

Published today in Genome Research, the study examined a large collection of E. coli isolated from patients with bloodstream infection over more than a decade, some of which were resistant to numerous antibiotics while others were not.

news

The work could lead to a new generation of potential therapies for NPC1 and other similar disorders, as well as neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. The scientists reported their findings online on July 17, 2017 in the journal Autophagy.

news

Researchers from MIT and other institutions are hoping to use nanotechnology to develop more targeted treatments for these drug-resistant bugs. In a new study, they report that an antimicrobial peptide packaged in a silicon nanoparticle dramatically reduced the number of bacteria in the lungs of mice infected with Pseudomonas aeruginosa, a disease causing Gram-negative bacterium that can lead to pneumonia.

news

Imagine a drug regimen where an obese person would cycle between different drug therapies over the course of a month to achieve a greater degree of body weight loss compared to the effects achieved with either a single drug or the continuous combination of drugs," said senior author Dr. Matthew Hayes.

news

NEW YORK, June 29 (Reuters Breaking views) - New commissioner Scott Gottlieb is wasting no time combating high prices. The U.S. agency will expedite reviews of generic-drug applications to promote competition. The changes will batter the likes of Valeant and Cardinal Health, and cast a cloud over branded drug makers.

news

Hyderabad, Jun 26 () Takeda Pharmaceutical Company and Biological E Ltd (BE) have signed two licensing agreements for development and delivery of affordable combination vaccines for low and middle-income countries.

news

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) requested an additional clinical study as part of a complete response letter (CRL) to the company’s new drug application for lifitegrast for the signs and symptoms of dry eye disease in adults.

news

VistaGen Therapeutics Inc , a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders announced it has signed an exclusive sublicense agreement with BlueRock Therapeutics

news

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

news

Neurim Pharmaceuticals and Exeltis announced a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim’s new Rx PedPRM in Spain.

news

Steel trade groups representing Canada, the United States and Mexico said that any upgrade to the North American Free Trade Agreement (NAFTA) should require that manufacturers use more steel produced in the region in their products. The rules of origin, which stipulate that products must meet minimum NAFTA-wide content requirements…

news

Ireland’s Government is to invest €5m over the next five years in a new Pharmaceutical Manufacturing Technology Centre (PMTC) that will be headquartered at the University of Limerick.